# Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): Phase 3 study in Locally Advanced Pancreatic Carcinoma (LAPC) (230 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Sponsor type | Academic and hospital |
| Study | Surgery Versus Stereotactic Ablative Radiotherapy for Patients With Locally Advanced Pancreatic Cancer With Favourable Biological Response Following Induction Chemotherapy |
| NCT ID | NCT07867873 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Locally Advanced Pancreatic Carcinoma (LAPC) |
| Intervention types | procedure, radiation |
| Target enrollment | 230 |
| Posted | 2026-10-09 |
| Planned start | 2026-10-01 |
| Event | Newly registered study |
| Event date | 2026-10-09 |

## Why this score
- Phase 3: multi-site, larger budget.
- 230 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07867873). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.